Reports [94] on SelectMDx support data from four European countries [95], which showed that SelectMDx in the initial diagnosis of prostate cancer saves healthcare costs and increases QALYs compared with the current standard of care based on prostate biopsy for elevated prostate-specific antigen [95]. This evidence concerns the gene KLK3 and Familial prostate cancer.